Pilar Eroles

18PUBLICATIONS
43CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 22, 2024
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.

Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas

|Jan 11, 2024
Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines.

Marta Sanz-Álvarez, Melani Luque, Miriam Morales-Gallego

|Sep 28, 2023
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.

Marta Tapia, Cristina Hernando, María Teresa Martínez

|Apr 13, 2023
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.

Paula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues

|Feb 25, 2023
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.

Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano

|Nov 11, 2022
Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway.

Birlipta Pattanayak, Ana Lameirinhas, Sandra Torres-Ruiz

Pageof 3

Frequent Collaborators

8 joint publications

Ana Lluch

6 joint publications

Ana Rovira

6 joint publications

Juan Madoz-Gúrpide

5 joint publications

María Teresa Martínez